IXHL

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Incannex announced dosing of the first patient in the Phase 2 DReAMzz study evaluating IHL-42XAug 26, 2026
• Incannex begins participant screening in the Phase 2 DReAMzz trial of IHL-42X for obstructive sleep apneaJul 23, 2026
• Incannex Healthcare wins MedTech Breakthrough Award for IHL-42XMay 12, 2026
• Incannex strengthened the clinical development path for IHL-42X after positive Phase 2 resultsMar 12, 2026
• Incannex granted FDA Fast Track designation for IHL-42X in obstructive sleep apneaDec 3, 2025